Jan Eucker
Impact in
- Hematology top 2%
- Multiple Myeloma Research and Treatments
- Oncology top 5%
- Bone health and treatments
- Peptidase Inhibition and Analysis
Papers in
- Hematology 20
- Multiple Myeloma Research and Treatments 15
- Oncology 30
- Cancer Treatment and Pharmacology 8
- Bone health and treatments 6
- Co-authors
- Orhan Sezer (35 shared papers)Kurt Possinger (38 shared papers)Christian Jakob (25 shared papers)K. Possinger (17 shared papers)Ulrike Heider (19 shared papers)Ivana Zavrski (18 shared papers)Kathrin Niemöller (7 shared papers)Barbara Graf (6 shared papers)
- Journals
- European Journal Of Haematology (7 papers)Annals of Hematology (6 papers)Anti-Cancer Drugs (5 papers)Blood (4 papers)Mycoses (4 papers)
- Partner nations
- GermanyUnited StatesChina
In The Last Decade
Jan Eucker
86 papers receiving 2.8k citations
Peers
Comparison fields: 5 of 116
- Hematology 717
- Oncology 793
- Genetics 295
- Infectious Diseases 366
- Pathology and Forensic Medicine 307
Countries citing papers authored by Jan Eucker
This map shows the geographic impact of Jan Eucker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Eucker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Eucker more than expected).
Fields of papers citing papers by Jan Eucker
This network shows the impact of papers produced by Jan Eucker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Eucker. The network helps show where Jan Eucker may publish in the future.
Co-authors
The 25 scholars most cited alongside Jan Eucker, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 87 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2001 | 159 | |
| 2 | 2001 | 148 | |
| 3 | 1999 | 138 | |
| 4 | 2000 | 125 | |
| 5 | Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. | 2003 | 122 |
| 6 | 2001 | 120 | |
| 7 | 2008 | 114 | |
| 8 | 2012 | 103 | |
| 9 | Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro. | 2012 | 89 |
| 10 | 2002 | 89 | |
| 11 | 2002 | 82 | |
| 12 | 2005 | 70 | |
| 13 | Mucormycoses. | 2001 | 68 |
| 14 | 2013 | 59 | |
| 15 | 2002 | 58 | |
| 16 | 2003 | 56 | |
| 17 | 2011 | 49 | |
| 18 | 2013 | 46 | |
| 19 | 2023 | 46 | |
| 20 | 2010 | 45 |
About Jan Eucker
Jan Eucker is a scholar working on Hematology, Oncology, Genetics, Molecular Biology and Pathology and Forensic Medicine, having authored 87 papers that have together received 2.9k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (15 papers), Cancer Treatment and Pharmacology (8 papers), Chronic Lymphocytic Leukemia Research (7 papers), Antifungal resistance and susceptibility (7 papers), Fungal Infections and Studies (6 papers), Bone health and treatments (6 papers), Lymphoma Diagnosis and Treatment (5 papers) and Peroxisome Proliferator-Activated Receptors (4 papers). The work is most often cited by research in Hematology (717 citations), Oncology (793 citations), Genetics (295 citations), Infectious Diseases (366 citations) and Pathology and Forensic Medicine (307 citations). Jan Eucker has collaborated with scholars based in Germany, United States and China. Frequent co-authors include Orhan Sezer, Kurt Possinger, Christian Jakob, K. Possinger, Ulrike Heider, Ivana Zavrski, Kathrin Niemöller, Barbara Graf, Chuanbing Zang and Klaus‐Dieter Wernecke. Their work appears in journals such as European Journal Of Haematology, Annals of Hematology, Anti-Cancer Drugs, Blood and Mycoses.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.